Generic Name and Formulations:
Tranylcypromine (as sulfate) 10mg; tabs.
Concordia Pharmaceuticals Inc.
Indications for PARNATE:
Major depressive disorder in adults who have not responded adequately to other antidepressants (not for initial treatment).
30mg daily in divided doses. If inadequate response, may increase in 10mg/day increments every 1–3 weeks; usual max 60mg/day. Switching to/from other antidepressants: see full labeling.
See Interactions. Pheochromocytoma. Catecholamine-releasing paragangliomas. To avoid potentially severe or fatal interactions, allow sufficient drug-free interval (at least 1 week or 4–5 half lives; see full labeling) between tranylcypromine and non-selective H1 receptor antagonists, other MAOIs (eg, linezolid, IV methylene blue), SSRIs (eg, fluoxetine), SNRIs, tricyclic antidepressants, amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine, amphetamines, methylphenidates and derivatives, sympathomimetics, triptans, buspirone, carbamazepine, cyclobenzaprine, dextromethorphan, dopamine, hydroxytryptophan, levodopa, methyldopa, meperidine, milnacipran, rasagiline, reserpine, s-adenosyl-L-methionine (SAM-e), tapentadol, tetrabenazine, tryptophan, mirtazapine.
Suicidal thoughts and behaviors. Hypertensive crisis with significant tyramine use.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes in all patients. Hypertensive crisis with significant tyramine use; monitor and discontinue if occurs. Hyperthyroidism. Hypertension. Cardiovascular or cerebrovascular disorders. History of headaches. Assess BP prior to initiation and monitor closely during treatment. Screen for bipolar disorder, mania, or hypomania. Depression. Monitor for hepatotoxicity; discontinue if occurs. Possible increased risk of CNS effects in those with cirrhosis. Diabetes (monitor glucose). Discontinue at least 10 days before elective surgery. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy. Nursing mothers: not recommended.
See Contraindications. Do not start within 5 weeks of fluoxetine. Avoid high-tyramine foods and beverages (eg, aged cheese, aged/fermented meats, salami, pickled herring, chocolate, beer, yeast extract, sauerkraut, soybean products, broad beans) during and for 2 weeks after discontinuation. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, SAM-e, other MAOIs); discontinue if occurs. Caution with hypotensive drugs, β-blockers, CNS depressants (eg, opioids, alcohol, sedatives, hypnotics), altretamine, chlorpromazine, droperidol, entacapone, tolcapone, methadone, metoclopramide, oxcarbazepine. Increased hypoglycemia with concomitant insulin, antidiabetic agents; may need lower dose of these.
Dry mouth, dizziness, insomnia, sedation, headache, overexcitement, constipation, blurred vision, tremor; hypertensive crises, hypertension, postural hypotension, syncope, hepatitis, elevated liver enzymes, seizures (monitor).
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- RET Inhibitor Gets Breakthrough Treatment Status for Medullary Thyroid Cancer
- Physical Activity as a Lifestyle Factor Influencing Early Menopause
- Situation Framing, Language Can Influence Decision-Making
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Oral Contraceptives Associated With Ventricular Repolarization Alterations